← Eichor
Study identifier: NCT05325645 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Condition: Acute Schizophrenia  ·  Sponsor: Otsuka Pharmaceutical Co., Ltd.

PhasePhase 3
Planned participants450
Who can joinAll sexes, 18 Years to 64 Years
Healthy volunteersNo

About this study

Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia

This description comes directly from the study's public registry record.

Talk to the study team

Drug Information Center  ·  +81-3-6361-7314

Always discuss trial participation with your own doctor first.

Locations (1)

Hayakawa ClinicKure-shi, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05325645